FDA approves tesamorelin for HIV-related lipodystrophy.
Kate
K
Traynor
D050153:Abdominal Fat / Q000187:drug effects*; D017277:Drug Approval; D013007:Growth Hormone-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D013007:Growth Hormone-Releasing Hormone; C479538:tesamorelin